drugset / Trial / NCT00123292
Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the trial is to evaluate the safety and efficacy of microplasmin administration in patients with acute peripheral arterial occlusion.
Timeline
- Start
- 2005-03
- Primary completion
- 2007-06
- Completion
- 2009-11
Outcome
Outcome not reported
Stopped: “Sponsor's decision not to pursue development of uPLi for vascular conditions”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ocriplasmin | Protein / enzyme biologic | 0.45 mg/kg | Other |
| Subject | Ocriplasmin | Protein / enzyme biologic | 0.6 mg/kg | Other |
| Subject | Ocriplasmin | Protein / enzyme biologic | 0.9 mg/kg | Other |
| Subject | Ocriplasmin | Protein / enzyme biologic | 20 mg | Other |
| Subject | Ocriplasmin | Protein / enzyme biologic | 40 mg | Other |